Biosimilars Infocard - Procurement of biologics

Procurement of biologics


Manufacturers of innovator and biosimilar medicines should have equal opportunities to secure treatment volumes based on the overall value of the medicine for patients and the health care systems.

Usage Rights & Restrictions

This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.

Download (PDF 434.06 KB)